Attivare Therapeutics Inc https://validator.w3.org/feed/docs/rss2.html Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine AACR 2025 ATT-01 Poster AACR 2025 ATT-02 Poster Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025 Attivare Therapeutics Appoints David Sherris, Ph.D. as President, CEO, and Chairman Harvard’s Wyss Institute Gives Startup License to Use Newly-Developed Biomaterials Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies News Home UPDATES